Synapse - Robert Motzer

Results (1243)

Zanzalintinib in combination with immune checkpoint inhibitors: Design of the renal cell carcinoma expansion stage cohorts in STELLAR-002

Meeting Abstract

Motzer, R. J.; Choueiri, T. K.; Garmezy, B.; O'Neil, B.; Michalski, J.; Barata, P.; Bajaj, A.; Chahoud, J.; Liu, M.; Xu, F.; more...
The Oncologist (2023)

Fulltext@MSK | Save

Functional and translational consequences of immunometabolic coevolution in ccRCC

Meeting Abstract

Reznik, E.; Tang, C.; Xie, A.; Liu, E. M.; Kuo, F.; Kim, M.; Golkaram, M.; Chen, Y.; Gupta, S.; Motzer, R.; more...
The Oncologist (2023)

Fulltext@MSK | Save

Характеристики и методы лечения основных нежелательных явлений у пациентов с распространенным почечно-клеточным раком, получающих терапию комбинацией ленватиниба с пембролизумабом на основании результатов исследования CLEAR

Journal Article

Motzer, R.; George, S.; Merchan, J. R.; Hutson, T. E.; Song, X.; Perini, R. F.; Xie, R.; Bapat, U.; Puente, J.
Onkourologiya (2023)

Fulltext@MSK | Save

Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: Long-term follow-up results from JAVELIN Renal 101

Journal Article

Tomita, Y.; Motzer, R. J.; Choueiri, T. K.; Rini, B. I.; Miyake, H.; Oya, M.; Albiges, L.; Aizawa, M.; Umeyama, Y.; Wang, J.; more...
ESMO Open (2023)

Fulltext@MSK | Save

Patient-reported outcome measurement and reporting for patients with advanced renal cell carcinoma: A systematic literature review

Review

Motzer, R. J.; Rane, P. P.; Saretsky, T. L.; Pawar, D.; Martin Nguyen, A.; Sundaram, M.; Burgents, J.; Pandey, R.; Rudell, K.
European Urology (2023)

Fulltext@MSK | Save

Summary of research: Adjuvant nivolumab plus ipilimumab versus placebo for localized renal cell carcinoma after nephrectomy (CheckMate 914): A double-blind, randomized, phase 3 trial

Journal Article

Motzer, R. J.; Russo, P.; Grünwald, V.; Tomita, Y.; Zurawski, B.; Parikh, O.; Buti, S.; Barthélémy, P.; Goh, J. C.; Ye, D.; more...
Targeted Oncology (2023)

Fulltext@MSK | Save

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: Outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

Journal Article

Grünwald, V.; Powles, T.; Eto, M.; Kopyltsov, E.; Rha, S. Y.; Porta, C.; Motzer, R.; Hutson, T. E.; Méndez-Vidal, M. J.; Hong, S. H.; more...
Frontiers in Oncology (2023)

Fulltext@MSK | Save

Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB)

Meeting Abstract

Guercio, B. J.; Ratna, N.; Gavrilov, D.; Duzgol, C.; Akhlaq, M.; Teo, M. Y.; Regazzi, A. M.; Kotecha, R. R.; Funt, S. A.; Aggen, D. H.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Germline mutations in hereditary renal cell carcinoma (RCC) genes among 32,240 patients with all cancer types

Meeting Abstract

Carlo, M. I.; Schroeder, A.; Mukherjee, S.; Kemel, Y.; Kotecha, R. R.; Lee, C. H.; Shah, N. J.; Feldman, D. R.; Liu, Y. L.; Walsh, M. F.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma

Meeting Abstract

Fitzgerald, K. N.; Kotecha, R. R.; Knezevic, A.; Shapnik, N.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save